Musk enters the debate on the future of AI: hope for goodwill or a calculated risk?
A wave of debate over artificial intelligence safety has once again swept through Silicon Valley, and this time two of the industry's loudest voices are at the epicenter. Elon Musk unexpectedly backed the position of Anthropic CEO Dario Amodei, who has recently faced criticism for excessive pessimism in assessing AI development. My expertise in technology trends suggests this alliance could signal a serious shift in how risks are perceived.
Defending against accusations of alarmism
Amodei has had to justify himself before investors and colleagues who consider his forecasts too bleak. He counters that his position is far from one-sided: his essay "Machines of Loving Grace" addresses not only threats but also enormous benefits. The problem is that short interviews and speeches are taken out of context, creating a false impression of catastrophism. The deeper cause of distrust, he says, lies in society's long-standing skepticism toward technology corporations and government institutions, which is automatically projected onto AI.
This distrust directly affects the regulatory agenda. Amodei has already proposed mandatory testing of advanced models instead of voluntary commitments, and has warned the G7 about the danger of fragmented national rules. He acknowledges the fairness of criticism aimed at his industry: "We still haven't fulfilled the main promise—to bring benefit to the world."
The philosophical undertone of the dispute
Musk, commenting on Amodei's thread, called the dialogue "interesting" and effectively endorsed the key thesis of investor Naval Ravikant: you cannot create a god and put it on a leash. Musk's response was laconic and succinct: "I hope AI will be kind to us." This restrained admission reveals anxiety: if humanity loses control over superintelligence, the only hope left will be the machine's goodwill.
Notably, this is not the first time Musk has sided with Anthropic. He has repeatedly criticized OpenAI's closed nature, noting that Amodei chose a different path. At the same time, Amodei himself disputes the Silicon Valley conventional wisdom that regulation always leads to a concentration of power. For example, California's SB 53 bill, which Anthropic supports, actually exempts small companies with revenue below $500 million from excessive requirements.
As alternatives, Amodei considers two approaches: pre-release model testing, proposed by the Trump administration, and creating a regulator modeled on FINRA, an idea from Demis Hassabis of Google DeepMind. Ultimately, he returns to his most ambitious goal—AI in biology, which could cure most diseases within 5-10 years. For him, this is not an empty slogan but a personal story: his father died of hepatitis C when no treatments yet existed.
My analysis: The fact that figures like Musk and Amodei are openly discussing AI's "goodwill" speaks to the maturity of the debate. The market has not yet fully realized that regulatory risks could become the main factor influencing the value of AI companies. Investors should pay closer attention to these discussions—they will determine not only ethical norms but also the economics of the entire industry for decades to come.